Free Trial
NASDAQ:NKTR

Nektar Therapeutics (NKTR) Stock Price, News & Analysis

Nektar Therapeutics logo
$23.24 +0.52 (+2.27%)
As of 10:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Nektar Therapeutics Stock (NASDAQ:NKTR)

Key Stats

Today's Range
$22.61
$23.87
50-Day Range
$8.51
$29.68
52-Week Range
$6.48
$37.38
Volume
223,095 shs
Average Volume
486,599 shs
Market Capitalization
$288.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$88.33
Consensus Rating
Moderate Buy

Company Overview

Nektar Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
96th Percentile Overall Score

NKTR MarketRank™: 

Nektar Therapeutics scored higher than 96% of companies evaluated by MarketBeat, and ranked 90th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nektar Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Nektar Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Nektar Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Nektar Therapeutics are expected to decrease in the coming year, from ($0.72) to ($0.80) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nektar Therapeutics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nektar Therapeutics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nektar Therapeutics has a P/B Ratio of 4.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Nektar Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    4.98% of the float of Nektar Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Nektar Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nektar Therapeutics has recently decreased by 20.95%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Nektar Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Nektar Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.98% of the float of Nektar Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Nektar Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nektar Therapeutics has recently decreased by 20.95%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Nektar Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Nektar Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    41 people have searched for NKTR on MarketBeat in the last 30 days. This is an increase of 1,267% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $29,416.00 in company stock.

  • Percentage Held by Insiders

    Only 3.71% of the stock of Nektar Therapeutics is held by insiders.

  • Percentage Held by Institutions

    75.88% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Nektar Therapeutics' insider trading history.
Receive NKTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NKTR Stock News Headlines

Image of dna strand and data processing over world map on black background. Global technology, computing and digital interface concept digitally generated image. — Photo
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories?
Cropped view of man scratching hand with allergy isolated on grey
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.
See More Headlines

NKTR Stock Analysis - Frequently Asked Questions

Nektar Therapeutics' stock was trading at $13.95 on January 1st, 2025. Since then, NKTR shares have increased by 62.9% and is now trading at $22.73.

Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings results on Thursday, May, 8th. The biopharmaceutical company reported ($3.30) earnings per share for the quarter, missing analysts' consensus estimates of ($2.70) by $0.60. The biopharmaceutical company had revenue of $10.46 million for the quarter, compared to the consensus estimate of $15.61 million. Nektar Therapeutics had a negative trailing twelve-month return on equity of 329.54% and a negative net margin of 152.49%.
Read the conference call transcript
.

Shares of Nektar Therapeutics reverse split on the morning of Monday, June 9th 2025.A 1-15 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Nektar Therapeutics' top institutional investors include Parallel Advisors LLC (0.01%). Insiders that own company stock include Deep Track Capital, Lp, Howard W Robin, Mark Andrew Wilson, Jillian B Thomsen, Jonathan Zalevsky, Robert Chess, Roy A Whitfield and Myriam Curet.
View institutional ownership trends
.

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nektar Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Bristol Myers Squibb (BMY), Netflix (NFLX) and Exxon Mobil (XOM).

Company Calendar

Last Earnings
5/08/2025
Today
7/09/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:NKTR
CIK
906709
Employees
220
Year Founded
1990

Price Target and Rating

High Price Target
$120.00
Low Price Target
$30.00
Potential Upside/Downside
+274.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$118.96 million
Net Margins
-152.49%
Pretax Margin
-147.55%

Debt

Sales & Book Value

Annual Sales
$98.43 million
Price / Cash Flow
N/A
Book Value
$4.94 per share
Price / Book
4.78

Miscellaneous

Free Float
11,947,000
Market Cap
$292.90 million
Optionable
Optionable
Beta
0.94

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:NKTR) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners